Certara, Inc. (NASDAQ:CERT) Shares Bought by Bellevue Group AG

Bellevue Group AG grew its holdings in Certara, Inc. (NASDAQ:CERT) by 5.2% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 95,924 shares of the company’s stock after purchasing an additional 4,709 shares during the quarter. Bellevue Group AG owned approximately 0.06% of Certara worth $1,715,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of the company. Mubadala Investment Co PJSC purchased a new position in Certara during the fourth quarter worth approximately $169,135,000. Wasatch Advisors LP increased its position in shares of Certara by 23.4% in the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after acquiring an additional 932,598 shares in the last quarter. Geneva Capital Management LLC increased its position in shares of Certara by 29.0% in the fourth quarter. Geneva Capital Management LLC now owns 3,824,850 shares of the company’s stock worth $67,279,000 after acquiring an additional 860,763 shares in the last quarter. Norges Bank acquired a new stake in shares of Certara in the fourth quarter worth $14,262,000. Finally, Massachusetts Financial Services Co. MA increased its position in shares of Certara by 22.5% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 2,585,155 shares of the company’s stock worth $45,473,000 after acquiring an additional 475,081 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Certara Price Performance

Shares of NASDAQ:CERT traded down $0.42 on Monday, reaching $15.30. 233,958 shares of the company traded hands, compared to its average volume of 569,834. Certara, Inc. has a fifty-two week low of $11.81 and a fifty-two week high of $19.87. The company’s 50 day moving average is $15.34 and its 200-day moving average is $16.58. The stock has a market capitalization of $2.46 billion, a PE ratio of -40.31, a P/E/G ratio of 5.42 and a beta of 1.53. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.26 and a quick ratio of 3.26.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.06 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.01). The company had revenue of $96.65 million for the quarter, compared to analyst estimates of $94.48 million. Certara had a negative net margin of 17.02% and a positive return on equity of 4.08%. As a group, analysts anticipate that Certara, Inc. will post 0.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on CERT shares. JMP Securities reissued a “market perform” rating on shares of Certara in a research report on Wednesday, July 10th. Barclays lowered their price target on shares of Certara from $18.00 to $16.00 and set an “equal weight” rating for the company in a report on Friday, June 28th. Finally, KeyCorp lowered their price target on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, July 11th. Seven analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $19.44.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.